Coller Capital has closed its first RMB-denominated GP-led transaction with Legend Capital, worth 315 million yuan ($45.8 million) and comprising six healthcare assets, according to a company statement on Tuesday. 

Just earlier this month, Coller Capital announced the first close of its maiden RMB secondaries fund with a total target size of 1.5 billion yuan ($218 million). This deal is its first from the maiden RMB fund. 

The six assets come under four sub-sectors within the healthcare industry: digital health, medical services, medical devices, and diagnostic technology, per the statement. 

The transaction marks the third between Coller Capital and Legend Capital. In May 2021, Hamilton Lane and Coller Capital co-led a $270-million fund restructuring deal of healthcare assets owned by Legend Capital.

In July last year, Coller Capital alongside South Korean private equity firm Hahn & Company co-led a $1.5 billion GP-led transaction in a Korean cement manufacturer, the largest transaction of its kind in Asia.

“As the secondary market in China is becoming increasingly active, secondaries have become more and more important as an exit strategy of private equity funds, which also puts forward higher requirements for GP’s transaction ability,” said Jafar Wang, Legend Capital’s co-chief investment officer.

London-headquartered Coller Capital is one of the world’s largest investors in the secondary market for private assets. It provides liquidity solutions to investors globally, acquiring interests in private equity, private credit, and other private market assets. 

Founded in 2001, Legend Capital is a venture capital and private equity investor focusing on early-stage and growth-stage opportunities in China. It currently manages USD and RMB funds of over $10 billion in commitments and has invested in the technology, healthcare, consumer, enterprise service, and intelligent manufacturing sectors.